| First Author | Wang H | Year | 2022 |
| Journal | Int Immunopharmacol | Volume | 110 |
| Pages | 109025 | PubMed ID | 35853280 |
| Mgi Jnum | J:327824 | Mgi Id | MGI:7334584 |
| Doi | 10.1016/j.intimp.2022.109025 | Citation | Wang H, et al. (2022) PLGA microspheres carrying miR-20a-5p improved intestinal epithelial barrier function in patients with Crohn's disease through STAT3-mediated inhibition of Th17 differentiation. Int Immunopharmacol 110:109025 |
| abstractText | BACKGROUND: Recent studies have shown that microRNAs (miRNAs) are aberrantly expressed in patients with Crohn's disease (CD). This suggests that the aberrant expression of miRNAs may contribute to the development of CD. Currently, the specific miRNAs involved in CD development have not been clearly identified. Therefore, we aimed to identify CD-associated miRNAs and explore their functions. METHODS: miRNA microarray analysis was performed to screen for differentially expressed miRNAs in colon tissues from normal controls (NC) and CD patients. The identified miRNAs were validated using quantitative real-time PCR (qPCR). The therapeutic roles of miR-20a-5p mimics via the delivery of poly(lactic-co-glycolic acid) microspheres (PLGA MSs) were further investigated in IL-10(-/-) mice with spontaneous chronic colitis that were used as a model of CD. The target genes of miR-20a-5p and the associated signaling pathways were identified through bioinformatic analysis and experimental verification of the interactions between the targets predicted by the algorithms and dysregulated mRNAs. RESULTS: The analysis showed that miR-20a-5p was the most significantly downregulated miRNA in patients with CD. Treatment with PLGA MSs carrying miR-20a-5p significantly ameliorated the colitis, decreased mucosal inflammation, and improved epithelial barrier function. Bioinformatic analysis and experimental studies showed that miR-20a-5p inhibition enhanced Th17 differentiation and improved intestinal epithelial barrier function by targeting STAT3. CONCLUSIONS: Downregulation of miR-20a-5p improved the intestinal epithelial barrier function and prevented CD development through the STAT3/IL-17 signaling pathway. Therefore, the delivery of miR-20a-5p by PLGA MSs may serve as a potential therapeutic strategy for CD treatment. |
